Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Two years after Terumo Corp. spiked a distribution deal with Boston Scientific for its GlideWire urology device, the Japanese company turned to Olympus.
The exclusive deal calls for Olympus Medical Systems Group’s urology and stone management sales force to distribute Terumo’s GlideWire urologic hydrophilic coated guidewire in the U.S. Read more
Reimbursement issues have become 1 of the top concerns for medtech startups, a panel at a Minneapolis conference said yesterday. In the past, FDA regulations, clinical trials, or finding investors might’ve been the top worry for those in the medical device field, but reimbursement and payment issues have climbed to the top of the list, according to speakers at LifeScience Alley’s “Leading the Conversation in Medtech” event.
Three medical device CEOs and a moderator who works with helping medtech firms solve reimbursement issues discussed the topic in an panel entitled, “Reimbursement for Investors and Entrepreneurs,” and agreed that reimbursement has never been more important for the industry. Read more
ConforMIS unveiled plans for an initial public offering worth up to $172.5 million, saying it plans to file for FDA approval of its customized hip implant this year.
Bedford, Mass.-based ConforMIS said it plans to trade on the NASDAQ exchange under the CFMS symbol. The company originally filed confidentially March 20, according to the SEC. Read more